Arcus Ventures co-leads $27m Exosome Diagnostics financing round


Opsona research labArcus Ventures has co-led a $27m financing round for molecular diagnostics business Exosome Diagnostics alongside industry player QIAGEN.

Other new capital came from Tiger Partners, CD Ventures and Monashee Capital, while previous backers including NGN Capital and Forbion Capital Partners also renewed their commitments tp the business.

The company is preparing to launch its first clinical diagnostics product in the US, which will use a urine sample and potentially cut down on the number of unnecessary prostate biopsies.

Arcus general partners Steven Soignet said, “Exosome Diagnostics technology will advance cancer care by allowing the collection of longitudinal molecular information that can potentially improve the use of cancer therapeutics and may serve as a method to diagnose and assess for recurrence of disease.”

Copyright © 2014 AltAssets